Literature DB >> 19513512

Dual functional molecular imaging probe targeting CD20 with PET and optical imaging.

Pramila Paudyal1, Bishnuhari Paudyal, Yasuhiko Iida, Noboru Oriuchi, Hirofumi Hanaoka, Hideyuki Tominaga, Tomohiro Ishikita, Hiroki Yoshioka, Tetsuya Higuchi, Keigo Endo.   

Abstract

The present study aimed to develop a monoclonal antibody (mAb)-based double functional probe for PET and near-infrared fluorescence (NIRF) targeting CD20 and to cross validate the targeting efficacy of this dual functional probe. NuB2, anti CD20 mAb was conjugated with Alexa Fluor 750 and 64Cu through DOTA chelator. PET and NIRF imaging was carried out at 30 min and 24 h post-injection with 64Cu-DOTA-NuB2-Alexa Fluor 750 in CD20 positive Raji lymphoma-bearing mice. Fluorescence intensity and radio-activity were studied by ex vivo biodistribution study at 30 min, 24 and 48 h after injection. Raji tumor showed significantly higher uptake of DOTA-NuB2-Alexa Fluor 750 than that of DOTA-Alexa Fluor 750 (p<0.05). Significant correlation was obtained between the organ-to-muscle ratios measured by the radioactivity and fluorescence intensity (p<2.2e-16, r=0.94). Our findings demonstrate the effectiveness and feasibility of preparing an effective mAb-based dual functional imaging agent for PET and NIRF targeting the CD20 expression in lymphoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513512     DOI: 10.3892/or_00000413

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging.

Authors:  Md Kausar Alam; Ayman El-Sayed; Kris Barreto; Wendy Bernhard; Humphrey Fonge; C Ronald Geyer
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

Review 2.  Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.

Authors:  S Lütje; M Rijpkema; W Helfrich; W J G Oyen; O C Boerman
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

Review 3.  Recent trends in antibody-based oncologic imaging.

Authors:  Sukhwinder Kaur; Ganesh Venktaraman; Maneesh Jain; Shantibhusan Senapati; Pradeep K Garg; Surinder K Batra
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

Review 4.  Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

Authors:  Christopher G England; Lixin Rui; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-14       Impact factor: 9.236

Review 5.  Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology.

Authors:  Fei-Fei An; Mark Chan; Harikrishna Kommidi; Richard Ting
Journal:  AJR Am J Roentgenol       Date:  2016-05-25       Impact factor: 3.959

Review 6.  Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.

Authors:  Ali Azhdarinia; Pradip Ghosh; Sukhen Ghosh; Nathaniel Wilganowski; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

7.  Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.

Authors:  Brian M Zeglis; Charles B Davis; Dalya Abdel-Atti; Sean D Carlin; Aimei Chen; Robert Aggeler; Brian J Agnew; Jason S Lewis
Journal:  Bioconjug Chem       Date:  2014-11-26       Impact factor: 4.774

Review 8.  Image guided biodistribution and pharmacokinetic studies of theranostics.

Authors:  Hong Ding; Fang Wu
Journal:  Theranostics       Date:  2012-11-05       Impact factor: 11.556

9.  In vivo tomographic imaging with fluorescence and MRI using tumor-targeted dual-labeled nanoparticles.

Authors:  Yue Zhang; Bin Zhang; Fei Liu; Jianwen Luo; Jing Bai
Journal:  Int J Nanomedicine       Date:  2013-12-16

Review 10.  Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development.

Authors:  Uwe Seibold; Björn Wängler; Ralf Schirrmacher; Carmen Wängler
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.